HIV assays used, by study site.

<p>HIV assays used, by study site.</p

HIV test results.

<p>HIV test results.</p

PreScreening Data and Other Characteristics of Partners HSV-2 Study Sites

*<p>2004 or 2005 census data.</p>**<p>From PEPFAR (http//<a href="http://www.pepfar.gov/" target="_blank">www.pepfar.gov/</a>): “National HIV-1 prevalence among adults aged 15–49” for each country listed.</p> ˆ<p>Clinical trial recruitment also extended to outlying districts with total population of 0.75–1.5 million persons.</p>#<p>Source of HIV-1 prevalence data: Kenya-reference <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001411#pone.0001411-Kenyan1" target="_blank">[23]</a>; Uganda–reference <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001411#pone.0001411-Ministry1" target="_blank">[7]</a>; Tanzania–reference <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001411#pone.0001411-Kapiga1" target="_blank">[24]</a>; S. Africa–reference <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001411#pone.0001411-Dorrington1" target="_blank">[25]</a>; Zambia–reference <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001411#pone.0001411-Zambia1" target="_blank">[26]</a>; Botswana–reference <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001411#pone.0001411-UN2" target="_blank">[27]</a>.</p>&<p>-Total number of couples receiving HIV counseling and testing during previously defined recruitment periods: July 2005–April 2006 (Ndola and Kitwe, Zambia) and December 2006–April 2007 (all other Partners HSV-2 Study sites).</p>@<p>-NHRI calculated from PEPFAR data (http//<a href="http://www.pepfar.gov/" target="_blank">www.pepfar.gov/</a>) as: (“# individuals receiving counseling and testing in settings other than PMTCT in FY2006”+“# HIV-1 infected individuals receiving palliative care/basic health care and support in FY2006 (including HIV-1/TB)”)/“Adults and children (age 0–49) living with HIV-1 at the end of 2005”.</p

Study Schema.

<p>Study Schema.</p

Baseline Characteristics of Enrolled HIV-1 Serodiscordant Couples (N = 4758).

<p>*Any contraceptive use includes: oral, injectable and implantable contraceptives, intrauterine device, hysterectomy or bilateral tubal ligation.</p><p>**Data on sexually transmitted infections available from a subset of participants.</p

Study Inclusion and Exclusion Criteria.

<p>Study Inclusion and Exclusion Criteria.</p

Study Site Laboratory Assays.

<p>*Jinja & Kampala used Vironostika 3^rd gen until March 2010.</p><p>**Tororo & Mbale used Roche C111 until Sept 2010. </p><p>Kabwohe used ^†Immutrep RPR, and</p>‡<p>Determine Syphilis TP until May 2010.</p